Back to discover

Protein / target

ADP/ATP translocase 1

Encoded bySLC25A4P12235Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
GO CC high conf
1
Research papers

Protein at a glance

Biological role

Oxidative phosphorylation uncoupler

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene SLC25A4 · Genetic evidence · score 0.68

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell.

View complete UniProt function annotation

ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (PubMed:21586654, PubMed:27693233, PubMed:23173940, PubMed:30046662). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then dissociating from the substrate binding site before the second substrate binds for transport in the opposite direction (PubMed:37278158). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (PubMed:31883789). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A4/ANT1 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death (PubMed:31883789). It is however unclear if SLC25A4/ANT1 constitutes a pore-forming component of mPTP or regulates it (By similarity). Acts as a regulator of mitophagy independently of ADP:ATP antiporter activity: promotes mitophagy via interaction with TIMM44, leading to inhibit the presequence translocase TIMM23, thereby promoting stabilization of PINK1 (By similarity)

Subcellular location

Mitochondrion inner membraneMembrane
Domains and Gene Ontology detail (19)

Gene Ontology

  • Cmembrane
  • Cmitochondrial inner membrane
  • Cmitochondrial membrane
  • Cmitochondrial permeability transition pore complex
  • Cmitochondrion
  • Cplasma membrane
  • Fadenine transmembrane transporter activity
  • FATP binding
  • FATP:ADP antiporter activity
  • Foxidative phosphorylation uncoupler activity
  • Fproton transmembrane transporter activity
  • Padaptive thermogenesis

298 aa · 33 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt
View supporting evidence

Lipid & lipoprotein metabolism

  • ·ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP syn…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SLC25A4

Gene-level evidence surfaced through the gene SLC25A4 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.41

Cardiomyopathy, Hypertrophic
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.46

Neurodegenerative Diseases
0.35Preliminary

Pathway evidence dominant · Open Targets 0.53 · no direct causal or clinical evidence

View evidence synthesis (3)
Genetic Diseases, InbornModerately supported
0.68
agreement 0.540.82
Genetic99%Literature1%

Open Targets aggregate 0.41 · 2 independent evidence families

Cardiomyopathy, HypertrophicModerately supported
0.56
agreement 0.420.70
Genetic98%Literature2%Genetic literaturedup

Open Targets aggregate 0.46 · 2 independent evidence families · 1 not counted as duplicate

Neurodegenerative DiseasesPreliminary
0.35
agreement 0.170.53
Pathway97%Literature3%

Open Targets aggregate 0.53 · 2 independent evidence families · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.53
Cardiomyopathy, Hypertrophic0.46
Genetic Diseases, Inborn0.41

Tractability

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.